yh002
mAbexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 22, 2020 (NCT04353102)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
TNFSF4 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06245954 | N/A | Mar 1, 2024 | Peking University |
| NCT05169697 | Phase 1 | Feb 21, 2022 | Eucure (Beijing) Biopharma Co., Ltd, Zhejiang University |
| NCT04388423 | N/A | May 31, 2020 | People's Liberation Army of China |
| NCT04353102 | Phase 1 | Apr 22, 2020 | Eucure (Beijing) Biopharma Co., Ltd |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eucure (Beijing) Biopharma Co., Ltd | For profit | 2 | 2 | 1 | 2020 |
| Peking University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| People's Liberation Army of China | Government | 1 | 1 | 1 | 2020 |
| Zhejiang University | Academic/Hospital | 1 | 0 | 1 | 2022 |
4 organizations
Page 1 / 1